Coherus Oncology, Inc. (CHRS)
NASDAQ: CHRS · Real-Time Price · USD
0.3871
-0.0228 (-5.56%)
At close: Nov 19, 2026, 4:00 PM EST
0.4000
+0.0129 (3.33%)
After-hours: Nov 19, 2026, 7:30 PM EST
Coherus Oncology Stock Forecast
CHRS's stock price has decreased by -68.01% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
According to 6 analysts polled by S&P Global, Coherus Oncology stock has a consensus rating of "Buy" and an average price target of $7.25. The average 1-year stock price forecast is 1,772.90% higher than the current stock price, while the lowest is $4.00 (+933.32%) and the highest is $10 (+2,483.31%).
Price Target: $7.25 (+1,772.90%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Coherus Oncology stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Apr '26 | May '26 | Jun '26 | Aug '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 5 | 5 | 4 | 4 | 4 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 7 | 7 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Buy Maintains $10 → $8 | Buy | Maintains | $10 → $8 | +1,966.65% | Nov 10, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Maintains $7 | Buy | Maintains | $7 | +1,708.32% | Nov 10, 2026 |
| Maxim Group | Maxim Group | Buy Reiterates $4 | Buy | Reiterates | $4 | +933.32% | Oct 30, 2026 |
| Oppenheimer | Oppenheimer | Buy Maintains $10 | Buy | Maintains | $10 | +2,483.31% | Aug 6, 2026 |
| TD Cowen | TD Cowen | Buy Maintains n/a | Buy | Maintains | n/a | n/a | May 28, 2026 |
Financial Forecast
Revenue This Year
56.71M
from 42.17M
Increased by 34.48%
Revenue Next Year
87.50M
from 56.71M
Increased by 54.28%
EPS This Year
-0.90
from -1.36
EPS Next Year
-0.62
from -0.90
EPS and Forward PE are based on non-GAAP adjusted numbers.